Clinical practice guide for the care to children and adolescents with chronic renal disease
Keywords:
clinical practice guide, chronic renal disease, primary health care.Abstract
Chronic renal disease constitutes a health problem due to its impact on individuals, society and economy. Taking into account the above-mentioned, and after a wide literature search, a clinical practice guide was designed in Luis Augusto Turcios Lima Polyclinic from Pinar del Río province, directed to primary health care professionals, aimed at improving the life quality of children and adolescents with this disease. It was elaborated by medicine methods based on the evidence, according to the consent and opinion of experts. It was possible to generalize this tool, give recommendations and up to date according to the new medical evidences. Finally, it was evaluated by experts as very recommended.Downloads
Download data is not yet available.
References
1. Centers for Disease Control and Prevention. Chronic Kidney Disease in the United States, 2023. Atlanta, GA: US Department of Health and Human Services; 2023 [citado 04/01/2023]. Disponible en: https://www.cdc.gov/kidneydisease/pdf/CKD-Factsheet-H.pdf
2. Cuba. Ministerio de Salud Pública. Dirección Nacional de Estadística. Anuario Estadístico de Salud 2022. La Habana: MINSAP; 2023 [citado 04/01/2023]. Disponible en: https://files.sld.cu/dne/files/2023/10/Anuario-Estadistico-de-Salud-2022-Ed-20231.pdf
3. Romero N, Pérez N, Pérez P, Pérez K, Reyes J, Rodríguez A. Causas de enfermedad renal entre los pacientes de una unidad de hemodiálisis. Rev. cuban. urol. 2019 [citado 04/01/2023];8(1). Disponible en: https://revurologia.sld.cu/index.php/rcu/article/view/461/498
4. Madrid. Grupo de trabajo sobre actualización de GPC. Elaboración de GPC en el Sistema Nacional de Salud. Actualización del manual metodológico. Madrid: Ministerio de Sanidad, Servicios Sociales e Igualdad [citado 04/01/2023]. Disponible en: https://portal.guiasalud.es/wp-content/uploads/2019/01/manual_gpc_completo.pdf
5. Cheung AF, Chang TI, Cushman WC, Furth SL, Hou FF, Ix JH, et al. KDIGO 2021. Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021 [citado 04/01/2023];99(3):S1-S87. Disponible en: https://www.kidney-international.org/article/S0085-2538(20)31270-9/fulltext
6. Fernández Camblor C, Melgosa Hijosa M. Enfermedad renal crónica (ERC) en la infancia: diagnóstico y tratamiento. Protoc Diagn Ter Pediatr. 2014 [citado 04/01/2023];1. Disponible en: https://www.aeped.es/sites/default/files/documentos/24_erc_diag_trat.pdf
7. Alvarado HR, Casallas Vega A, Andrade Fonseca D, Bertolotto AM. Calidad de vida en los niños que viven con enfermedad renal crónica. Investig Enfermer Imag Desarr. 2019 [citado 04/01/2023];21(2). Disponible en: https://revistas.javeriana.edu.co/index.php/imagenydesarrollo/article/view/25448
8. García Maset R, Bover J, Segura de la Morena J, Goicoechea Diezhandino M, Cebollada del Hoyo J, Escalada San Martín J, et al. Documento de información y consenso para la detección y manejo de la enfermedad renal crónica. Nefrología. 2022 [citado 04/01/2023];42(3):233–64. Disponible en: https://revistanefrologia.com/es-documento-informacion-consenso-deteccion-manejo-articulo-S0211699521001612
9. Centro Nacional de Excelencia Tecnológica en Salud de México. Guía de práctica clínica. Prevención, diagnóstico y tratamiento de la enfermedad renal crónica. Evidencias y recomendaciones:. México: CENETEC; 2019 [citado 04/01/2023]. Disponible en: http://www.cenetec-difusion.com/CMGPC/GPC-IMSS-335-19/ER.pdf
10. Heerspink HJL, Greene T, Tighiouart H, Gansevoort RT, Coresh J, Simon AL. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes Endocrinol. 2019 [citado 04/01/2023]; 7(2):128-39. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30635226/
11. Shlipak MG, Tummalapalli SL, Boulware LB, Grams ME, Ix JH, Jha V, et al. The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2021 [citado 04/01/2023];99(1):134-47. Disponible en: https://www.kidney-international.org/article/S0085-2538(20)31210-2/fulltext
12. Hinojoza Alarcón G, Paramio Rodríguez A. La microalbuminuria en el diagnóstico precoz del daño renal en pacientes diabéticos. Finlay. 2021 [citado 04/01/2023]; 11(2). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S2221-24342021000200122
13. Thompson A, Carroll K, Inker LA, Floege J, Perkovic V, Boyer Suavet S, et al. Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol. 2019 [citado 04/01/2023];14(3):469–81. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419287/
14. Coresh J, Heerspink HJL, Sang Y, Matsushita K, Arnlov J, Astor BC. Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes Endocrinol. 2019 [citado 04/01/2023]; 7(2). Disponible en: http://dx.doi.org/10.1016/S2213-8587(18)30313-9
15. Levey AS, Gansevoort RT, Coresh J, Inker LA, Heerspink HL, Grams ME, et al. Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency. Am J Kidney Dis. 2020 [citado 04/01/2023];75(1). Disponible en: https://www.ajkd.org/article/S0272-6386(19)30883-2/fulltext
16. Thompson A, Smith K, Lawrence J. Change in estimated GFR and albuminuria as end points in clinical trials: a viewpoint from the FDA. Am J Kidney Dis. 2020 [citado 04/01/2023];75(1). Disponible en: https://www.ajkd.org/article/S0272-6386(19)30946-1/fulltext
17. Donate Correa J, Tagua VG, Ferri C, Martín Núñez E, Hernández Carballo C, Ureña Torres P, et al. Pentoxifylline for renal protection in diabetic Kidney Disease. A model of old drugs for New Horizons. J Clin Med. 2019 [citado 04/01/2023]; 8(3). Disponible en: https://www.mdpi.com/2077-0383/8/3/287
18. American Diabetes Association. Introduction: Standards of Medical Care in Diabetes−2019. Diabetes Care. 2019 [citado 04/01/2023]; 42(Suppl.1). Disponible en: https://diabetesjournals.org/care/article/42/Supplement_1/S1/31271/Introduction-Standards-of-Medical-Care-in-Diabetes
19. Rodríguez Ramos JF, Herrera Miranda GL. Propuesta de guía de práctica clínica corta para el manejo de la enfermedad renal crónica. Medisur. 2023 [citado 04/01/2023];21(1). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1727-897X2023000100248
20. Halbach S. Practical application of ABPM in the pediatric nephrology clinic. Pediatr Nephrol. 2020 [citado 04/01/2023];35(11):2067–2076. Disponible en: https://link.springer.com/article/10.1007/s00467-019-04361-0
21. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019. ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020 [citado 04/01/2023];41(3):407-77. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31504439/
22. Henning RJ. Diagnosis and treatment of heart failure with preserved left ventricular ejection fraction. World J Cardiol. 2020 [citado 04/01/2023];12(1): 7-25. Disponible en: https://www.wjgnet.com/1949-8462/full/v12/i1/7.htm
23. Duan Y, Sun J, Zhao M, Magnussen CG, Xi B. Utility of blood pressure measurements at an initial screening visit to identify Chinese children and adolescents with hypertension. J Clin Hypertens (Greenwich). 2021 [citado 04/01/2023]; 23(4):766-72. Disponible en: https://onlinelibrary.wiley.com/doi/10.1111/jch.14127
24. Burnier M, Lin S, Ruilope L, Bader G, Durg S, Brunel P. Effect of angiotensin receptor blockers on blood pressure and renal function in patients with concomitant hypertension and chronic kidney disease: a systematic review and meta-analysis. Blood Press. 2019 [citado 04/01/2023];28(6):358-74. Disponible en: https://www.tandfonline.com/doi/full/10.1080/08037051.2019.1644155
25. Dolui S, Detre JA, Gaussoin SA, Herrick JS, Wang DJJ, Tamura MK, et al. Association of Intensive vs Standard Blood Pressure Control With Cerebral Blood Flow: Secondary Analysis of the SPRINT MIND Randomized Clinical Trial. JAMA Neurol. 2022 [citado 04/01/2023];79(4):380-9. Disponible en: https://jamanetwork.com/journals/jamaneurology/fullarticle/2789504
2. Cuba. Ministerio de Salud Pública. Dirección Nacional de Estadística. Anuario Estadístico de Salud 2022. La Habana: MINSAP; 2023 [citado 04/01/2023]. Disponible en: https://files.sld.cu/dne/files/2023/10/Anuario-Estadistico-de-Salud-2022-Ed-20231.pdf
3. Romero N, Pérez N, Pérez P, Pérez K, Reyes J, Rodríguez A. Causas de enfermedad renal entre los pacientes de una unidad de hemodiálisis. Rev. cuban. urol. 2019 [citado 04/01/2023];8(1). Disponible en: https://revurologia.sld.cu/index.php/rcu/article/view/461/498
4. Madrid. Grupo de trabajo sobre actualización de GPC. Elaboración de GPC en el Sistema Nacional de Salud. Actualización del manual metodológico. Madrid: Ministerio de Sanidad, Servicios Sociales e Igualdad [citado 04/01/2023]. Disponible en: https://portal.guiasalud.es/wp-content/uploads/2019/01/manual_gpc_completo.pdf
5. Cheung AF, Chang TI, Cushman WC, Furth SL, Hou FF, Ix JH, et al. KDIGO 2021. Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021 [citado 04/01/2023];99(3):S1-S87. Disponible en: https://www.kidney-international.org/article/S0085-2538(20)31270-9/fulltext
6. Fernández Camblor C, Melgosa Hijosa M. Enfermedad renal crónica (ERC) en la infancia: diagnóstico y tratamiento. Protoc Diagn Ter Pediatr. 2014 [citado 04/01/2023];1. Disponible en: https://www.aeped.es/sites/default/files/documentos/24_erc_diag_trat.pdf
7. Alvarado HR, Casallas Vega A, Andrade Fonseca D, Bertolotto AM. Calidad de vida en los niños que viven con enfermedad renal crónica. Investig Enfermer Imag Desarr. 2019 [citado 04/01/2023];21(2). Disponible en: https://revistas.javeriana.edu.co/index.php/imagenydesarrollo/article/view/25448
8. García Maset R, Bover J, Segura de la Morena J, Goicoechea Diezhandino M, Cebollada del Hoyo J, Escalada San Martín J, et al. Documento de información y consenso para la detección y manejo de la enfermedad renal crónica. Nefrología. 2022 [citado 04/01/2023];42(3):233–64. Disponible en: https://revistanefrologia.com/es-documento-informacion-consenso-deteccion-manejo-articulo-S0211699521001612
9. Centro Nacional de Excelencia Tecnológica en Salud de México. Guía de práctica clínica. Prevención, diagnóstico y tratamiento de la enfermedad renal crónica. Evidencias y recomendaciones:. México: CENETEC; 2019 [citado 04/01/2023]. Disponible en: http://www.cenetec-difusion.com/CMGPC/GPC-IMSS-335-19/ER.pdf
10. Heerspink HJL, Greene T, Tighiouart H, Gansevoort RT, Coresh J, Simon AL. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes Endocrinol. 2019 [citado 04/01/2023]; 7(2):128-39. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30635226/
11. Shlipak MG, Tummalapalli SL, Boulware LB, Grams ME, Ix JH, Jha V, et al. The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2021 [citado 04/01/2023];99(1):134-47. Disponible en: https://www.kidney-international.org/article/S0085-2538(20)31210-2/fulltext
12. Hinojoza Alarcón G, Paramio Rodríguez A. La microalbuminuria en el diagnóstico precoz del daño renal en pacientes diabéticos. Finlay. 2021 [citado 04/01/2023]; 11(2). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S2221-24342021000200122
13. Thompson A, Carroll K, Inker LA, Floege J, Perkovic V, Boyer Suavet S, et al. Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol. 2019 [citado 04/01/2023];14(3):469–81. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419287/
14. Coresh J, Heerspink HJL, Sang Y, Matsushita K, Arnlov J, Astor BC. Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes Endocrinol. 2019 [citado 04/01/2023]; 7(2). Disponible en: http://dx.doi.org/10.1016/S2213-8587(18)30313-9
15. Levey AS, Gansevoort RT, Coresh J, Inker LA, Heerspink HL, Grams ME, et al. Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency. Am J Kidney Dis. 2020 [citado 04/01/2023];75(1). Disponible en: https://www.ajkd.org/article/S0272-6386(19)30883-2/fulltext
16. Thompson A, Smith K, Lawrence J. Change in estimated GFR and albuminuria as end points in clinical trials: a viewpoint from the FDA. Am J Kidney Dis. 2020 [citado 04/01/2023];75(1). Disponible en: https://www.ajkd.org/article/S0272-6386(19)30946-1/fulltext
17. Donate Correa J, Tagua VG, Ferri C, Martín Núñez E, Hernández Carballo C, Ureña Torres P, et al. Pentoxifylline for renal protection in diabetic Kidney Disease. A model of old drugs for New Horizons. J Clin Med. 2019 [citado 04/01/2023]; 8(3). Disponible en: https://www.mdpi.com/2077-0383/8/3/287
18. American Diabetes Association. Introduction: Standards of Medical Care in Diabetes−2019. Diabetes Care. 2019 [citado 04/01/2023]; 42(Suppl.1). Disponible en: https://diabetesjournals.org/care/article/42/Supplement_1/S1/31271/Introduction-Standards-of-Medical-Care-in-Diabetes
19. Rodríguez Ramos JF, Herrera Miranda GL. Propuesta de guía de práctica clínica corta para el manejo de la enfermedad renal crónica. Medisur. 2023 [citado 04/01/2023];21(1). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1727-897X2023000100248
20. Halbach S. Practical application of ABPM in the pediatric nephrology clinic. Pediatr Nephrol. 2020 [citado 04/01/2023];35(11):2067–2076. Disponible en: https://link.springer.com/article/10.1007/s00467-019-04361-0
21. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019. ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020 [citado 04/01/2023];41(3):407-77. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31504439/
22. Henning RJ. Diagnosis and treatment of heart failure with preserved left ventricular ejection fraction. World J Cardiol. 2020 [citado 04/01/2023];12(1): 7-25. Disponible en: https://www.wjgnet.com/1949-8462/full/v12/i1/7.htm
23. Duan Y, Sun J, Zhao M, Magnussen CG, Xi B. Utility of blood pressure measurements at an initial screening visit to identify Chinese children and adolescents with hypertension. J Clin Hypertens (Greenwich). 2021 [citado 04/01/2023]; 23(4):766-72. Disponible en: https://onlinelibrary.wiley.com/doi/10.1111/jch.14127
24. Burnier M, Lin S, Ruilope L, Bader G, Durg S, Brunel P. Effect of angiotensin receptor blockers on blood pressure and renal function in patients with concomitant hypertension and chronic kidney disease: a systematic review and meta-analysis. Blood Press. 2019 [citado 04/01/2023];28(6):358-74. Disponible en: https://www.tandfonline.com/doi/full/10.1080/08037051.2019.1644155
25. Dolui S, Detre JA, Gaussoin SA, Herrick JS, Wang DJJ, Tamura MK, et al. Association of Intensive vs Standard Blood Pressure Control With Cerebral Blood Flow: Secondary Analysis of the SPRINT MIND Randomized Clinical Trial. JAMA Neurol. 2022 [citado 04/01/2023];79(4):380-9. Disponible en: https://jamanetwork.com/journals/jamaneurology/fullarticle/2789504
Published
2024-04-05
How to Cite
1.
Rodríguez Ramos JF, Miranda GLH. Clinical practice guide for the care to children and adolescents with chronic renal disease. MEDISAN [Internet]. 2024 Apr. 5 [cited 2025 Jul. 6];28(2):e4568. Available from: https://medisan.sld.cu/index.php/san/article/view/4568
Issue
Section
Special contribution
License
All the articles can be downloaded or read for free. The journal does not charge any amount of money to the authors for the reception, edition or the publication of the articles, making the whole process completely free. Medisan has no embargo period and it is published under the license of Creative Commons, International Non Commercial Recognition 4.0, which authorizes the copy, reproduction and the total or partial distribution of the articles in any format or platform, with the conditions of citing the source of information and not to be used for profitable purposes.
![Secimed](/templates/images/secimed.png"){kind=small}
